Metformin, which demonstrated browning in rats [44], showed no effect on the amount of BAT in humans (women with polycystic ovary syndrome [45] and patients with metabolic syndrome combined with human immunodeficiency virus); GLP1 receptor agonists promote weight loss and improve all the cardiometabolic parameters studied by us (glucose, lipids, BP) through several alternative mechanisms. The gene discussed is GLP1R; the disease is metabolic syndrome.